IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 46

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Dec 14, 2025; 31(46): 111631
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.111631

Table 1 The expression level of IGF2BP3 protein in two groups

^cP < 0.001.

Citation: Si Y, Tian B, Zhang R, Xuan MD, Liu KY, Jiao J, Han SS, Li HF, Hu YH, Zhao HY, He WJ, Wang J, Liu T, Yu WF. IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression. World J Gastroenterol 2025; 31(46): 111631
URL: https://www.wjgnet.com/1007-9327/full/v31/i46/111631.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i46.111631

Si Y, Tian B, Zhang R, Xuan MD, Liu KY, Jiao J, Han SS, Li HF, Hu YH, Zhao HY, He WJ, Wang J, Liu T, Yu WF. IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression. World J Gastroenterol 2025; 31(46): 111631 [PMID: 41479643 DOI: 10.3748/wjg.v31.i46.111631]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.